oxidopamine has been researched along with Adipocere in 4 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To examine neurotrophic abnormality in Parkinson's disease (PD), we measured the protein content of EGF, TGFalpha, and HB-EGF in post-mortem brains of patients with Parkinson's disease and age-matched control subjects." | 1.33 | Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons. ( Iwakura, Y; Kakita, A; Mizuno, M; Nawa, H; Piao, YS; Takahashi, H; Takei, N, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nilsson, A | 1 |
| Fälth, M | 1 |
| Zhang, X | 1 |
| Kultima, K | 1 |
| Sköld, K | 1 |
| Svenningsson, P | 1 |
| Andrén, PE | 1 |
| Hu, X | 1 |
| Weng, Z | 1 |
| Chu, CT | 1 |
| Zhang, L | 1 |
| Cao, G | 1 |
| Gao, Y | 1 |
| Signore, A | 1 |
| Zhu, J | 1 |
| Hastings, T | 1 |
| Greenamyre, JT | 1 |
| Chen, J | 1 |
| Charron, G | 1 |
| Doudnikoff, E | 1 |
| Laux, A | 1 |
| Berthet, A | 1 |
| Porras, G | 1 |
| Canron, MH | 1 |
| Barroso-Chinea, P | 1 |
| Li, Q | 1 |
| Qin, C | 1 |
| Nosten-Bertrand, M | 1 |
| Giros, B | 1 |
| Delalande, F | 1 |
| Van Dorsselaer, A | 1 |
| Vital, A | 1 |
| Goumon, Y | 1 |
| Bezard, E | 1 |
| Iwakura, Y | 1 |
| Piao, YS | 1 |
| Mizuno, M | 1 |
| Takei, N | 1 |
| Kakita, A | 1 |
| Takahashi, H | 1 |
| Nawa, H | 1 |
4 other studies available for oxidopamine and Adipocere
| Article | Year |
|---|---|
Striatal alterations of secretogranin-1, somatostatin, prodynorphin, and cholecystokinin peptides in an experimental mouse model of Parkinson disease.
Topics: Amino Acid Sequence; Animals; Cholecystokinin; Chromogranin B; Disease Models, Animal; Enkephalins; | 2009 |
Peroxiredoxin-2 protects against 6-hydroxydopamine-induced dopaminergic neurodegeneration via attenuation of the apoptosis signal-regulating kinase (ASK1) signaling cascade.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Animals; Apomorphine; Brain; Cell Differentiation; Ce | 2011 |
Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aged; alpha-Methyltyrosine; Analysis of Variance; Anim | 2011 |
Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons.
Topics: Adrenergic Agents; Aged; Aged, 80 and over; Animals; Blotting, Western; Disease Models, Animal; Drug | 2005 |